Pfizer sinks capital in healthcare research and cutting-edge science
Date: 2018-06-11   Author: Saipriya Iyer  Category: #industry

Pfizer sinks capital in healthcare research and cutting-edge science

Pharma magnate Pfizer reportedly aims to pour in close to USD 600 million in the field of biotechnology. As per authentic sources, the company also plans to invest capital in other emerging growth companies via its investment arm called Pfizer Ventures.

If reports are to be believed, Pfizer Ventures will be looking forward to investing around 25% of its available capital (amounting to USD 150 million) in early-stage neuroscience firms that are a mainstream part of the healthcare industry. Pfizer will be able to support early neuroscience research programs and product development opportunities by leveraging an equity investment model, or so believes the company.

Expressing her views regarding the investment and the current healthcare industry scenario, Barbara Dalton, Senior Managing Partner, Pfizer Ventures, and VP, Pfizer Worldwide Business Development, says that the company hopes to expand its support for developing cutting-edge science from concept to products by means of extending Pfizer’s venture capital efforts under Pfizer Ventures.

Presently, from the portfolio of Pfizer Ventures, six company investments have their point of focus on breakthrough neuroscience, inclusive of Cortexyme, Neuronetics, MISSION, Aquinnah, MindImmune, and Autifony. In addition, Pfizer has reportedly been instrumental in the development, sponsoring, and the launch of the Dementia Discovery Fund.

Sources claim that initially, Pfizer Ventures would be concentrating on the domains of neuro-inflammation, neuro-metabolic disorders, and neuro-degeneration where the robust rate of advancements may lead to breakthrough discoveries.

Speaking on the company’s contribution toward the healthcare industry via neuroscience, Denis Patrick, Managing Partner of Pfizer Ventures and VP, Pfizer Worldwide Research & Development, stated that the company hopes to transform the investment scenario in neuroscience and support a community of biotechnology entrepreneurs who are in the process of understanding the molecular mechanisms of neurologic diseases.

For the record, apart from investing in biotechnology, Pfizer plans to consolidate its stance as a market leader in venture capital investment. The company will reportedly accomplish the same with an expanded team that will be responsible for leveraging expertise across business development, clinical development, drug discovery, and venture capital investment.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Amazon India launches ‘Select’ program to assist emerging brands
Author: Saif Ali Bepari

E-commerce giant Amazon has reportedly started a new program called ‘Select’ in India. As per trusted sources, the program will enable emerging brands in the country to get access to a suite of brand buildi...


Equatorial Guinea set to launch new oil & gas bid round in January
Author: Saif Ali Bepari

Equatorial Guinea has reportedly announced that it will be launching a new bidding round for oil & gas exploration in the first quarter of 2019. According to reports, the bidding round would be for oil & gas ex...


Water companies submit plans to cut prices across England and Wales
Author: Saif Ali Bepari

Water companies have reportedly laid out plans to slash bills for millions of households in England and Wales. As per trusted sources, companies like United Utilities and Severn Trent have announced plans to reduce lea...